Loading…

Enovis CorporationENOVCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties

Maker of orthopedic devices and surgical/recovery solutions, including joint implants, braces and prevention/recovery products.

Momentum leader 82
Mkt cap
$1.56B
US dollars, full cap
Free float
98%
of shares outstanding
$/day
$45.4M
20-day average traded
Fwd P/E
7.6×
forward earnings
ROIC−WACC
-5.7 pp
WACC 8.2%
Hurdle
+26 pp
Req g minus delivered
Next earnings
99 days
25 Feb 2027
Close · USD$27.10
1D-0.4%
1W-5.1%
1M+31.0%
3M+3.5%
6M+2.4%
YTD+1.7%
1Y-4.2%
ATR %5.3%
Beta0.97
52w lowhigh14.4% off high

What Enovis does

Maker of orthopedic devices and surgical/recovery solutions, including joint implants, braces and prevention/recovery products.

Was the industrial company Colfax until it spun off its welding business, ESAB, in 2022, and renamed itself Enovis around the medical devices it had built up, including the DJO bracing business and, from 2024, the Italian implant maker Lima. Implants are bought by hospitals on surgeon preference.

Products and services

  • Joint reconstruction implants (hip/knee)
  • Prevention & recovery (bracing, bone growth stimulation)
  • Surgical instruments/robotics

Customers

  • Orthopedic surgeons
  • Physical therapists
  • Hospitals/ASCs

Where it sits in the supply chain

  • Medical devices
  • Orthopedics
  • Joint reconstruction implants, braces…

What could go right

  • Outpatient orthopedic surgery growth
  • Sports medicine/recovery product demand

What could go wrong

  • Scale disadvantage vs larger ortho majors
  • Hospital/ASC capex cyclicality

Moat: narrow (brand, installed base). Established orthopedic recovery/bracing brand plus a smaller joint-implant business competing against larger majors.

Headquarters: Wilmington, Delaware · Founded: 2022 · Employees: 7,802

Named competitors

Enovis at a glance

Size Enovis (ENOV) is a United States Health Care company (Medical Specialties) with a market value of $1.56B, the 1949th largest of 3,085 United States companies the cockpit tracks. Shares closed at $27.10 on 18 Nov 2026.

Performance Over six months the shares gained 2.4%, against -2.3% for the median peer and -2.2% for the United States market (cap-weighted) — 10th highest of 21 in its peer set.

Growth Revenue grew 3.3% over the last twelve months (peer median +8.6%); the operating margin is 3.9% (peer median 9.7%).

Valuation It trades at 7.6× forward earnings against a peer median of 24.5× (2nd cheapest of 18).

Price implies For today's price to make sense, revenue must grow about 20% a year for seven years (Req g). Recent delivered growth is -6%, so the hurdle is +26 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 5.7 points below its cost of capital (8.2% WACC).

Credit Enovis has 1 bond outstanding ($460M).

Short interest Short interest is 18.3% of the free float (30 Oct 2026).

Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026ENOV 110Peer median 100
Six months, rebased to 100: Enovis against the median of its 20 peers (local-currency closes).

Enovis financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$2.31B$2.25B$2.11B$1.71B$1.56B
Revenue growth—+7%+23%+9%—
Gross profit$1.23B$1.17B$1.03B$853M$737M
EBITDA$386M$297M$281M$212M$176M
Net income-$526M-$1.18B-$825M-$48.8M-$15.0M
Free cash flow$69.6M$19.9M-$67.2M$12.8M-$161M
Capital expenditure$189M$197M$181M$122M$105M
Total debt$1.34B$1.38B$1.40B$536M$335M

Quarterly statements and history in the cockpit →

Enovis competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%+40%-20%0%+20%VITR68496880166885313010876699BFLYELN8086300049INSP300298KMTSPRCTCNMDEMBLA301363LMATCHEMMENOV6-month return →1-month return →
Up and to the right = strong over both horizons. Enovis is the large dot.

Fundamentals: revenue growth against valuation

0%+25%+50%+75%20×40×VITR68496880166885313010876699ELN8086300049INSPXRAYCNMDEMBLA301363LMATCHEMMENOVRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Enovis is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%VITR68496880163010876699ELN300049INSP300298CNMDEMBLA301363LMATCHEMMENOVGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Enovis is the large dot.

Enovis competitors and peer comparison

Head to head with its named competitors (ENOV vs SYK vs ZBH vs SN..L)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Enovis ENOV$1.56B+2%+3%4%7.6×20.0%
Stryker SYK$121B-1%+8%25%19.9×10.7%
Zimmer Biomet ZBH$19.6B+21%+7%16%11.7×7.4%
Smith & Nephew SN..L$12.6B+1%+2%17%14.2×11.1%

How Enovis compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Enovis against its 20 peers (data as of 18 Nov 2026)
MeasureENOVPeer medianRank in peer set
1-month return+31.0%-1.1%2nd highest of 21
6-month return+2.4%-2.3%10th highest of 21
Distance from 52-week high-14.4%-26.7%6th highest of 21
Revenue growth (TTM)+3.3%+8.6%8th lowest of 21
Operating margin3.9%9.7%6th lowest of 21
Forward P/E7.6×24.5×2nd cheapest of 18
Growth the price implies (Req g, 7 yrs)20.0%11.2%4th most demanding of 16
Growth delivered (Del g)-6.0%+12.9%lowest of 16
Hurdle (Req g minus delivered)+26.1 pp-6.8 ppmost demanding of 16
ROIC minus cost of capital-5.7 pp+2.3 pp8th lowest of 21
EV / EBITDA7.5×14.0×2nd cheapest of 11
Net debt / EBITDA3.5×-1.1×4th most indebted of 12

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Enovis ENOVUnited States$1.56B+2%+3%4%7.6×20.0%-6.0%
Vitrolife VITR.STSweden$1.57B+13%-2%19%27.0×22.2%+22.5%
Nihon Kohden 6849.TJapan$1.55B+3%0%7%18.8×-3.5%+3.3%
Shanghai MicroPort Endovascular MedTech 688016.SSChina$1.55B-19%+16%44%16.4×2.7%+23.4%
Wuxi Unicomp Technology 688531.SSChina$1.58B-49%+53%12%35.8×n/an/a
Cofoe Medical Technology 301087.SZChina$1.60B-6%+33%10%25.1×11.2%+7.4%
Angelalign Technology 6699.HKHong Kong$1.62B-8%+84%9%52.5×16.7%+25.8%
Butterfly Network BFLYUnited States$1.63B+38%+39%-36%n/an/an/a
El.En ELN.MIItaly$1.46B+11%+3%15%22.0×10.7%+7.7%
NIPRO 8086.TJapan$1.68B-11%+5%5%15.8×n/an/a
Inner Mongolia Furui Medical Science 300049.SZChina$1.45B-31%+11%25%41.9×2.9%+14.6%
Inspire Medical Systems INSPUnited States$1.68B+32%0%2%41.3×28.7%+51.2%
Sinocare 300298.SZChina$1.45B+4%+7%6%21.5×9.5%+18.3%
Kestra Medical Technologies KMTSUnited States$1.69B+36%+61%-134%n/an/an/a
PROCEPT BioRobotics PRCTUnited States$1.45B-10%+17%-34%n/an/an/a
DENTSPLY SIRONA XRAYUnited States$1.69B-13%-1%5%6.8×11.2%+1.9%
CONMED CNMDUnited States$1.43B+30%+2%2%10.4×31.6%+9.8%
Embla Medical hf EMBLA.CODenmark$1.72B+1%+6%14%17.2×-1.9%+8.3%
Mehow Innovative 301363.SZChina$1.72B-36%+10%21%34.2×16.4%+12.9%
LeMaitre Vascular LMATUnited States$1.73B-25%+12%28%24.5×2.9%+14.0%
ChemoMetec A/S CHEMM.CODenmark$1.77B+107%+3%49%46.7×19.4%+12.7%

Enovis bonds and credit

Enovis has 1 bond outstanding with $460M face value.

Every bond, yield and spread in the cockpit →

Questions

Who are Enovis's main competitors?
Named competitors: Stryker (SYK), Zimmer Biomet (ZBH), Smith & Nephew (SN..L). The cockpit's measured peer set (industry) also includes Vitrolife (VITR.ST), Nihon Kohden (6849.T), Shanghai MicroPort Endovascular MedTech (688016.SS), Wuxi Unicomp Technology (688531.SS), Cofoe Medical Technology (301087.SZ), Angelalign Technology (6699.HK).
Is Enovis expensive compared with its peers?
On forward p/e it trades at 7.6× against a peer median of 24.5×, 2nd cheapest of 18 in its peer set. For today's price to make sense, revenue must grow about 20% a year for seven years (Req g). Recent delivered growth is -6%, so the hurdle is +26 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Enovis stock performed?
Over six months to 18 Nov 2026 the shares returned +2.4% against -2.3% for the median peer; over one year -4.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.